1. Home
  2. STTK vs TG Comparison

STTK vs TG Comparison

Compare STTK & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$5.47

Market Cap

652.4M

Sector

Health Care

ML Signal

N/A

Logo Tredegar Corporation

TG

Tredegar Corporation

N/A

Current Price

$7.51

Market Cap

239.6M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
TG
Founded
2016
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
652.4M
239.6M
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
STTK
TG
Price
$5.47
$7.51
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
★ $15.40
N/A
AVG Volume (30 Days)
★ 1.1M
210.0K
Earning Date
11-13-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
53.02
★ 151.06
EPS
N/A
★ 0.34
Revenue
$1,000,000.00
★ $800,821,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$22.12
Revenue Growth
N/A
★ 8.29
52 Week Low
$1.72
$6.25
52 Week High
$8.33
$10.53

Technical Indicators

Market Signals
Indicator
STTK
TG
Relative Strength Index (RSI) 41.15 51.91
Support Level $5.19 $7.06
Resistance Level $7.66 $8.22
Average True Range (ATR) 0.36 0.33
MACD 0.03 -0.03
Stochastic Oscillator 27.58 42.34

Price Performance

Historical Comparison
STTK
TG

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

Share on Social Networks: